Front Page News
Tell Your Senator to Support Innovations for Healthier Americans
We need your help in contacting your Senators to tell them that legislation promoting innovation and research is extremely important to you and that the […]
Read More ›Cure SMA Welcomes the North Jersey Chapter
Cure SMA is pleased to announce the creation of a new chapter in northern New Jersey, serving families and supporters with zip codes starting with […]
Read More ›Cure SMA and Other Venture Philanthropy Leaders Share Insight at Partnering for Cures Panel
Cure SMA President Kenneth Hobby was a featured panelist at Partnering for Cures, a conference convened by the Milken Institute’s FasterCures initiative. At the event, […]
Read More ›Cytokinetics Announces New Details on Upcoming Phase 2 Trial
Cytokinetics, in collaboration with Astellas, has announced further details about a planned Phase 2 clinical trial of CK-2127107 in patients with spinal muscular atrophy (SMA). […]
Read More ›Cure SMA Publishes Journal Article on the Patient Voice
Cure SMA, along with collaborators from Biogen and the SMA Foundation, have published a paper in the journal BMC Neurology. Over the past year, we’ve […]
Read More ›Cure SMA-Funded Researchers Publish Paper in Journal Pediatrics
Cure SMA-funded researchers Rebecca Hurst Davis and Kathy Swoboda have published a paper, “Responses to Fasting and Glucose Loading in a Cohort of Well Children […]
Read More ›Isis Pharmaceuticals Announces SHINE, an Open-Label Extension Study
Isis Pharmaceuticals, Inc. announced that it has initiated an open-label extension study, SHINE. The SHINE study provides ISIS-SMNRx to infants and children with spinal muscular […]
Read More ›Cure SMA to Host Clinical and Regulatory Webinar
On Monday, November 9, Cure SMA will be hosting a one-hour webinar on clinical trials and regulatory topics. The webinar will be held at 11:00am […]
Read More ›PTC Announces New Clinical Trial Results at World Muscle Congress
PTC Therapeutics, in partnership with Roche and the SMA Foundation, recently announced new results from their ongoing Phase 2 trial of RG7800, a small molecule […]
Read More ›Community Update on ISIS-SMNRx from Biogen and Isis
Biogen and Isis Pharmaceuticals recently provided an update on the clinical development of ISIS-SMNRx, which is currently being tested in Phase 3 clinical trials: Dear […]
Read More ›